LXRX
Price
$0.82
Change
+$0.11 (+15.49%)
Updated
Dec 23, 04:59 PM (EDT)
79 days until earnings call
MNKD
Price
$7.00
Change
+$0.16 (+2.34%)
Updated
Dec 23, 04:59 PM (EDT)
71 days until earnings call
Ad is loading...

LXRX vs MNKD

Header iconLXRX vs MNKD Comparison
Open Charts LXRX vs MNKDBanner chart's image
Lexicon Pharmaceuticals
Price$0.82
Change+$0.11 (+15.49%)
Volume$132.79K
CapitalizationN/A
MannKind
Price$7.00
Change+$0.16 (+2.34%)
Volume$120.4K
CapitalizationN/A
LXRX vs MNKD Comparison Chart
Loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
LXRX vs. MNKD commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LXRX is a Hold and MNKD is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (LXRX: $0.71 vs. MNKD: $6.85)
Brand notoriety: LXRX and MNKD are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: LXRX: 154% vs. MNKD: 248%
Market capitalization -- LXRX: $258.36M vs. MNKD: $1.89B
LXRX [@Biotechnology] is valued at $258.36M. MNKD’s [@Biotechnology] market capitalization is $1.89B. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

LXRX’s FA Score shows that 1 FA rating(s) are green whileMNKD’s FA Score has 1 green FA rating(s).

  • LXRX’s FA Score: 1 green, 4 red.
  • MNKD’s FA Score: 1 green, 4 red.
According to our system of comparison, MNKD is a better buy in the long-term than LXRX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

LXRX’s TA Score shows that 5 TA indicator(s) are bullish while MNKD’s TA Score has 6 bullish TA indicator(s).

  • LXRX’s TA Score: 5 bullish, 2 bearish.
  • MNKD’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, both LXRX and MNKD are a good buy in the short-term.

Price Growth

LXRX (@Biotechnology) experienced а -11.80% price change this week, while MNKD (@Biotechnology) price change was +4.74% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.12%. For the same industry, the average monthly price growth was -2.87%, and the average quarterly price growth was +3.33%.

Reported Earning Dates

LXRX is expected to report earnings on Mar 12, 2025.

MNKD is expected to report earnings on Mar 04, 2025.

Industries' Descriptions

@Biotechnology (-2.12% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNKD($1.89B) has a higher market cap than LXRX($258M). MNKD YTD gains are higher at: 88.187 vs. LXRX (-53.288). MNKD has higher annual earnings (EBITDA): 68.8M vs. LXRX (-198.7M). LXRX (258M) and MNKD (252M) have equal amount of cash in the bank . LXRX has less debt than MNKD: LXRX (101M) vs MNKD (240M). MNKD has higher revenues than LXRX: MNKD (267M) vs LXRX (5.23M).
LXRXMNKDLXRX / MNKD
Capitalization258M1.89B14%
EBITDA-198.7M68.8M-289%
Gain YTD-53.28888.187-60%
P/E RatioN/A85.63-
Revenue5.23M267M2%
Total Cash258M252M102%
Total Debt101M240M42%
FUNDAMENTALS RATINGS
LXRX vs MNKD: Fundamental Ratings
LXRX
MNKD
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
59
Fair valued
75
Overvalued
PROFIT vs RISK RATING
1..100
10018
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
9340
P/E GROWTH RATING
1..100
2481
SEASONALITY SCORE
1..100
75n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LXRX's Valuation (59) in the Biotechnology industry is in the same range as MNKD (75). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Profit vs Risk Rating (18) in the Biotechnology industry is significantly better than the same rating for LXRX (100). This means that MNKD’s stock grew significantly faster than LXRX’s over the last 12 months.

LXRX's SMR Rating (99) in the Biotechnology industry is in the same range as MNKD (100). This means that LXRX’s stock grew similarly to MNKD’s over the last 12 months.

MNKD's Price Growth Rating (40) in the Biotechnology industry is somewhat better than the same rating for LXRX (93). This means that MNKD’s stock grew somewhat faster than LXRX’s over the last 12 months.

LXRX's P/E Growth Rating (24) in the Biotechnology industry is somewhat better than the same rating for MNKD (81). This means that LXRX’s stock grew somewhat faster than MNKD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
LXRXMNKD
RSI
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 4 days ago
82%
Bullish Trend 4 days ago
84%
Momentum
ODDS (%)
Bullish Trend 4 days ago
77%
Bullish Trend 4 days ago
90%
MACD
ODDS (%)
Bullish Trend 4 days ago
87%
N/A
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
86%
Bullish Trend 4 days ago
86%
TrendMonth
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
72%
Advances
ODDS (%)
Bullish Trend 15 days ago
81%
Bullish Trend 4 days ago
86%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 7 days ago
78%
BollingerBands
ODDS (%)
N/A
Bullish Trend 4 days ago
90%
Aroon
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
65%
View a ticker or compare two or three
Ad is loading...
LXRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNKD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
SVFKX79.361.11
+1.42%
Smead Value R2
TOCQX47.040.57
+1.23%
Tocqueville
ADJEX16.360.17
+1.05%
Azzad Ethical
QISCX27.060.24
+0.89%
Federated Hermes MDT Small Cap Core IS
LHCSX19.290.01
+0.05%
Lord Abbett Health Care R4

LXRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, LXRX has been loosely correlated with EPIX. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if LXRX jumps, then EPIX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LXRX
1D Price
Change %
LXRX100%
-1.23%
EPIX - LXRX
44%
Loosely correlated
N/A
FRTX - LXRX
41%
Loosely correlated
-0.34%
NTLA - LXRX
37%
Loosely correlated
+0.83%
BEAM - LXRX
37%
Loosely correlated
+8.04%
SPRO - LXRX
37%
Loosely correlated
-4.30%
More

MNKD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNKD has been loosely correlated with PGEN. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if MNKD jumps, then PGEN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNKD
1D Price
Change %
MNKD100%
+8.73%
PGEN - MNKD
47%
Loosely correlated
+5.07%
NTLA - MNKD
44%
Loosely correlated
+0.83%
VCYT - MNKD
44%
Loosely correlated
+4.66%
LXRX - MNKD
42%
Loosely correlated
-1.23%
INSM - MNKD
40%
Loosely correlated
+1.48%
More